CANCER:

Colorectal Cancer

Related cancers:

‹

Colon Cancer (95)

Rectal Cancer (41)

Colorectal Adenocarcinoma (5)

Colon Cancer (95)

Rectal Cancer (41)

Colorectal Adenocarcinoma (5)

›

MSI-H/dMMR MSI-H/dMMR	Colorectal Cancer CRC	nivolumab + ipilimumab Sensitive: A1 - Approval NICE - 3 days
KRAS G12V KRAS G12V	Colorectal Cancer CRC	FOLFOX Resistant: C3 – Early Trials Sci Rep - 2 weeks
KRAS G12D KRAS G12D	Colorectal Cancer CRC	FOLFOX Resistant: C3 – Early Trials Sci Rep - 2 weeks
KRAS mutation + ATM mutation KRAS mutation + ATM mutation	Rectal Cancer Rectal Cancer	bevacizumab Sensitive: C4 – Case Studies Onco Targets Ther - 2 weeks
MSI-H/dMMR MSI-H/dMMR	Colorectal Cancer CRC	pembrolizumab Sensitive: A1 - Approval ESMO-GI 2021 - 3 weeks
BRAF V600E BRAF V600E	Colorectal Cancer CRC	cetuximab + encorafenib + binimetinib Sensitive: A1 - Approval ESMO-GI 2021 - 3 weeks
BRAF V600E BRAF V600E	Colorectal Cancer CRC	cetuximab + encorafenib Sensitive: A1 - Approval ESMO-GI 2021 - 3 weeks
NRAS mutation NRAS mutation	Colorectal Cancer CRC	cetuximab Resistant: A2 - Guideline ESMO-GI 2021 - 3 weeks
BRAF mutation BRAF mutation	Colorectal Cancer CRC	cetuximab Resistant: B - Late Trials ESMO-GI 2021 - 3 weeks
KRAS mutation KRAS mutation	Colorectal Cancer CRC	cetuximab Resistant: B - Late Trials ESMO-GI 2021 - 3 weeks
KRAS exon 2 mutation KRAS exon 2 mutation	Colorectal Cancer CRC	bevacizumab Sensitive: C2 – Inclusion Criteria ESMO-GI 2021 - 3 weeks
MSI-H/dMMR + KRAS Mutation MSI-H/dMMR + KRAS Mutation	Colorectal Cancer CRC	nivolumab + ipilimumab Sensitive: C3 – Early Trials ESMO-GI 2021 - 3 weeks
MSI-H/dMMR + BRAF Mutation MSI-H/dMMR + BRAF Mutation	Colorectal Cancer CRC	nivolumab + ipilimumab Sensitive: C3 – Early Trials ESMO-GI 2021 - 3 weeks
PIK3CA mutation PIK3CA mutation	Colorectal Cancer CRC	cetuximab Resistant: C3 – Early Trials ESMO-GI 2021 - 3 weeks
ANGPT2-H ANGPT2-H	Colorectal Cancer CRC	regorafenib Sensitive: C3 – Early Trials ESMO-GI 2021 - 3 weeks
KRAS G12C KRAS G12C	Colorectal Cancer CRC	bevacizumab Resistant: C3 – Early Trials ESMO-GI 2021 - 3 weeks
MSI-H/dMMR + NTRK3 fusion MSI-H/dMMR + NTRK3 fusion	Colorectal Cancer CRC	larotrectinib Sensitive: C3 – Early Trials ESMO-GI 2021 - 3 weeks
MSI-H/dMMR + NTRK2 fusion MSI-H/dMMR + NTRK2 fusion	Colorectal Cancer CRC	larotrectinib Sensitive: C3 – Early Trials ESMO-GI 2021 - 3 weeks
MSI-H/dMMR + NTRK1 fusion MSI-H/dMMR + NTRK1 fusion	Colorectal Cancer CRC	larotrectinib Sensitive: C3 – Early Trials ESMO-GI 2021 - 3 weeks
PIK3CA mutation PIK3CA mutation	Colorectal Cancer CRC	ribociclib + alpelisib Sensitive: D – Preclinical ESMO-GI 2021 - 3 weeks
KRAS mutation KRAS mutation	Colorectal Cancer CRC	ribociclib + alpelisib Sensitive: D – Preclinical ESMO-GI 2021 - 3 weeks
No biomarker No biomarker	Colon Cancer Colon Cancer	capecitabine Sensitive: A1 - Approval
No biomarker No biomarker	Rectal Cancer Rectal Cancer	FOLFIRI Sensitive: A1 - Approval
No biomarker No biomarker	Colon Cancer Colon Cancer	5-fluorouracil + irinotecan Sensitive: A1 - Approval
No biomarker No biomarker	Colorectal Cancer CRC	bevacizumab Sensitive: A1 - Approval
No biomarker No biomarker	Rectal Cancer Rectal Cancer	Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Colon Cancer Colon Cancer	Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Colon Cancer Colon Cancer	Zirabev (bevacizumab biosimilar) Resistant: A1 - Approval
No biomarker No biomarker	Colorectal Cancer CRC	trifluridine/tipiracil Sensitive: A1 - Approval
No biomarker No biomarker	Colorectal Cancer CRC	ziv-aflibercept IV Sensitive: A1 - Approval
No biomarker No biomarker	Colorectal Cancer CRC	capecitabine Sensitive: A1 - Approval
EGFR expression EGFR expression	Colorectal Cancer CRC	cetuximab Sensitive: A1 - Approval
KRAS Q61 KRAS Q61	Colorectal Cancer CRC	cetuximab Resistant: A1 - Approval
No biomarker No biomarker	Colorectal Cancer CRC	ramucirumab Sensitive: A1 - Approval
No biomarker No biomarker	Colorectal Cancer CRC	panitumumab Sensitive: A1 - Approval
KRAS A146 KRAS A146	Colorectal Cancer CRC	cetuximab Resistant: A1 - Approval
No biomarker No biomarker	Rectal Cancer Rectal Cancer	irinotecan Sensitive: A1 - Approval
No biomarker No biomarker	Colon Cancer Colon Cancer	irinotecan Sensitive: A1 - Approval
KRAS G13 KRAS G13	Colorectal Cancer CRC	cetuximab Resistant: A1 - Approval
KRAS G12 KRAS G12	Colorectal Cancer CRC	cetuximab Resistant: A1 - Approval
No biomarker No biomarker	Colorectal Cancer CRC	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
MSI-H/dMMR MSI-H/dMMR	Colorectal Cancer CRC	nivolumab Sensitive: A1 - Approval
No biomarker No biomarker	Colorectal Cancer CRC	regorafenib Sensitive: A1 - Approval
KRAS K117 KRAS K117	Colorectal Cancer CRC	cetuximab Resistant: A1 - Approval
KRAS A59 KRAS A59	Colorectal Cancer CRC	cetuximab Resistant: A1 - Approval
KRAS G12S KRAS G12S	Colorectal Cancer CRC	panitumumab Resistant: A1 - Approval
NRAS Q61 NRAS Q61	Colorectal Cancer CRC	cetuximab Resistant: A1 - Approval
NRAS Q61 NRAS Q61	Colorectal Cancer CRC	panitumumab Resistant: A1 - Approval
NRAS G13 NRAS G13	Colorectal Cancer CRC	panitumumab Resistant: A1 - Approval
NRAS G13 NRAS G13	Colorectal Cancer CRC	cetuximab Resistant: A1 - Approval
NRAS G12 NRAS G12	Colorectal Cancer CRC	panitumumab Resistant: A1 - Approval
NRAS G12 NRAS G12	Colorectal Cancer CRC	cetuximab Resistant: A1 - Approval
NRAS A146 NRAS A146	Colorectal Cancer CRC	cetuximab Resistant: A1 - Approval
NRAS A146 NRAS A146	Colorectal Cancer CRC	panitumumab Resistant: A1 - Approval
KRAS G13 KRAS G13	Colorectal Cancer CRC	panitumumab Resistant: A1 - Approval
KRAS G61 KRAS G61	Colorectal Cancer CRC	panitumumab Resistant: A1 - Approval
KRAS A146 KRAS A146	Colorectal Cancer CRC	panitumumab Resistant: A1 - Approval
NRAS H117 NRAS H117	Colorectal Cancer CRC	cetuximab Resistant: A1 - Approval
NRAS H117 NRAS H117	Colorectal Cancer CRC	panitumumab Resistant: A1 - Approval
NRAS A59 NRAS A59	Colorectal Cancer CRC	cetuximab Resistant: A1 - Approval
NRAS A59 NRAS A59	Colorectal Cancer CRC	panitumumab Resistant: A1 - Approval
KRAS K117 KRAS K117	Colorectal Cancer CRC	panitumumab Resistant: A1 - Approval
KRAS A59 KRAS A59	Colorectal Cancer CRC	panitumumab Resistant: A1 - Approval
NRAS exon 4 mutation NRAS exon 4 mutation	Colorectal Cancer CRC	panitumumab Resistant: A1 - Approval
NRAS exon 3 mutation NRAS exon 3 mutation	Colorectal Cancer CRC	panitumumab Resistant: A1 - Approval
NRAS exon 2 mutation NRAS exon 2 mutation	Colorectal Cancer CRC	panitumumab Resistant: A1 - Approval
NRAS mutation NRAS mutation	Colorectal Cancer CRC	panitumumab Resistant: A1 - Approval
NRAS exon 4 mutation NRAS exon 4 mutation	Colorectal Cancer CRC	cetuximab Resistant: A1 - Approval
No biomarker No biomarker	Colorectal Cancer CRC	Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Rectal Cancer Rectal Cancer	Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Colon Cancer Colon Cancer	Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Colorectal Cancer CRC	Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Colorectal Cancer CRC	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
HER-2 amplification HER-2 amplification	Colorectal Cancer CRC	trastuzumab + pertuzumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Colon Cancer Colon Cancer	CAPOX Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Colon Cancer Colon Cancer	FOLFOX Sensitive: A2 - Guideline
No biomarker No biomarker	Colon Cancer Colon Cancer	oxaliplatin Sensitive: A2 - Guideline
No biomarker No biomarker	Colon Cancer Colon Cancer	CAPOX Sensitive: A2 - Guideline
No biomarker No biomarker	Colon Cancer Colon Cancer	FOLFOX Sensitive: A2 - Guideline
KRAS G13D KRAS G13D	Colorectal Cancer CRC	panitumumab Resistant: A2 - Guideline
KRAS G13D KRAS G13D	Colorectal Cancer CRC	cetuximab Resistant: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Colorectal Cancer CRC	pembrolizumab + ipilimumab Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Rectal Cancer Rectal Cancer	nivolumab Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Colorectal Cancer CRC	larotrectinib Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Colorectal Cancer CRC	larotrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Colorectal Cancer CRC	larotrectinib Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Colorectal Cancer CRC	entrectinib Sensitive: A2 - Guideline
NTRK2 fusion NTRK2 fusion	Colorectal Cancer CRC	entrectinib Sensitive: A2 - Guideline
NTRK1 fusion NTRK1 fusion	Colorectal Cancer CRC	entrectinib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Colorectal Cancer CRC	panitumumab + encorafenib Sensitive: A2 - Guideline
BRAF V600E BRAF V600E	Colorectal Cancer CRC	trametinib + dabrafenib + panitumumab Sensitive: A2 - Guideline
HER-2 amplification HER-2 amplification	Colorectal Cancer CRC	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
HER-2 amplification HER-2 amplification	Colorectal Cancer CRC	trastuzumab + lapatinib Sensitive: A2 - Guideline
NRAS exon 2 mutation NRAS exon 2 mutation	Colorectal Cancer CRC	cetuximab Resistant: A2 - Guideline
NRAS exon 3 mutation NRAS exon 3 mutation	Colorectal Cancer CRC	cetuximab Resistant: A2 - Guideline
BRAF V600E BRAF V600E	Colorectal Cancer CRC	cetuximab + trametinib + dabrafenib Sensitive: A2 - Guideline
No biomarker No biomarker	Colorectal Cancer CRC	bevacizumab + trifluridine/tipiracil Sensitive: A2 - Guideline
No biomarker No biomarker	Colorectal Cancer CRC	FOLFOXIRI Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	FOLFOXIRI Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	capecitabine Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	FOLFOX Sensitive: A2 - Guideline
No biomarker No biomarker	Colorectal Cancer CRC	cetuximab Sensitive: A2 - Guideline
No biomarker No biomarker	Colon Cancer Colon Cancer	5-fluorouracil + oxaliplatin + leucovorin calcium Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Rectal Cancer Rectal Cancer	pembrolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	CAPOX Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	bevacizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	5-fluorouracil Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Rectal Cancer Rectal Cancer	nivolumab + ipilimumab Sensitive: A2 - Guideline
No biomarker No biomarker	Rectal Cancer Rectal Cancer	trifluridine/tipiracil Sensitive: A2 - Guideline
HER-2 amplification HER-2 amplification	Rectal Cancer Rectal Cancer	trastuzumab + pertuzumab Sensitive: A2 - Guideline
HER-2 amplification HER-2 amplification	Rectal Cancer Rectal Cancer	trastuzumab + lapatinib Sensitive: A2 - Guideline
HER-2 amplification HER-2 amplification	Rectal Cancer Rectal Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline
NTRK3 fusion NTRK3 fusion	Rectal Cancer Rectal Cancer	larotrectinib Sensitive: A2 - Guideline

Colorectal Cancer

Associations(901)

Associations
(901)